Nitric Oxide‐dependent Vasodilatation of Rabbit Femoral Artery by Β2‐adrenergic Stimulation or Cyclic AMP Elevation in Vivo

B Xu,J Li,L Gao,A Ferro
DOI: https://doi.org/10.1038/sj.bjp.0703155
IF: 7.3
2000-01-01
British Journal of Pharmacology
Abstract:Some studies suggest that β‐adrenoceptor‐mediated vasorelaxation is in part mediated through nitric oxide (NO) release. We wished to determine the contribution of the L‐arginine / NO system to vasodilatation in response to β‐adrenoceptor stimulation with isoprenaline or cyclic adenosine‐3′,5′‐monophosphate (cyclic AMP) elevation with forskolin and dibutyryl cyclic AMP in vivo, using a rabbit femoral artery constant perfusion model. Baseline femoral artery pressure was similar in rabbits receiving isoprenaline, forskolin or dibutyryl cyclic AMP. Isoprenaline, forskolin and dibutyryl cyclic AMP each decreased femoral artery pressure in a dose‐dependent manner. The doses (mol kg−1) of isoprenaline, forskolin and dibutyryl cyclic AMP which decreased pressure by 10% from baseline, expressed as a negative logarithm (−log ED10) were: 10.0±0.2, 9.5±0.1 and 4.9±0.1 respectively (P<0.0001 for each). Use of β‐adrenoceptor subtype‐selective antagonists showed that the vascular response to isoprenaline was purely due to stimulation of the β2‐adrenoceptor subtype. Injection of 1 μmol kg−1 NG‐nitro‐L‐arginine methyl ester (L‐NAME) did not alter baseline pressure. However, it abolished the pressure response to isoprenaline (P<0.0001), and significantly attenuated the pressure responses to forskolin and dibutyryl cyclic AMP: −log ED10 values for forskolin and dibutyryl cyclic AMP, in the presence of L‐NAME, were 7.9±0.1 and 3.5±0.3 respectively (P<0.0001 for each, as compared with values in the absence of L‐NAME). These results indicate that β2‐adrenergic stimulation and cylic AMP elevation activate the L‐arginine/NO system in rabbit femoral artery in vivo, and that NO generation contributes importantly to the changes in vascular tone induced by agents which modulate β‐adrenoceptors or cyclic AMP. British Journal of Pharmacology (2000) 129, 969–974; doi:10.1038/sj.bjp.0703155
What problem does this paper attempt to address?